Höglander, Elen Kristine
Nord, Silje
Wedge, David C.
Lingjærde, Ole Christian
Silwal-Pandit, Laxmi
Gythfeldt, Hedda vdL
Vollan, Hans Kristian Moen
Fleischer, Thomas
Krohn, Marit
Schlitchting, Ellen
Borgen, Elin
Garred, Øystein
Holmen, Marit M.
Wist, Erik
Naume, Bjørn
Van Loo, Peter
Børresen-Dale, Anne-Lise
Engebraaten, Olav
Kristensen, Vessela
Funding for this research was provided by:
Red Ribbon for Breast Cancer Research
Norges Forskningsråd
Kreftforeningen (419616 - 71248 - PR-2006-0282)
Helse Sør-Øst RHF (2729004, 2014061)
F. Hoffmann-La Roche
Article History
Received: 14 August 2018
Accepted: 13 November 2018
First Online: 29 November 2018
Ethics approval and consent to participate
: Written informed consent forms were obtained from all patients. The study was approved by the Institutional Protocol Review Board of Oslo University Hospital, the Regional Committee for Medical and Health Research Ethics for South-Eastern Norway (ref. no. 2008/10187), and the Norwegian Medicines Agency and was carried out in accordance with the Declaration of Helsinki, International Conference on Harmony/Good Clinical practice.
: Not applicable.
: EKH is employed by Roche Norge AS since 01.10.2017. Roche Norge AS is a subsidiary of F. Hoffmann-La Roche Ltd. The data published in this article are based on research conducted with support from Hoffmann-La Roche. The study was planned and the results were interpreted and the article was written without the involvement of Roche Norge AS. Roche Norge AS supported the trial by funding study nurse, CRF, and monitoring of the data. Bevacizumab was supplied by Roche Norge AS. The research was conducted without any involvement by Hoffmann-La Roche and before EKH was employed by Roche Norge AS. Any personal views of EKH should not be understood or quoted as being made on behalf of or reflecting the position of Hoffmann-La Roche. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.